- In September 2024, Intas Pharmaceuticals Ltd. announced the launch of Azadine-O, the first-ever oral Azacitidine therapy for Acute Myeloid Leukemia (AML) in the Indian market. This groundbreaking development marks a major milestone in the Azacitidine market, providing patients with a more convenient and patient-friendly alternative to traditional injectable formulations
- In May 2022, the U.S. Food and Drug Administration (FDA) granted approval for azacitidine (Vidaza, Celgene Corp.) for use in pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). This approval marked a significant milestone in the Azacitidine market, expanding its therapeutic application beyond myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) to address a rare and aggressive form of childhood leukemia
- In September 2020, Hikma Pharmaceuticals PLC, a leading multinational pharmaceutical company, announced the launch of Azacitidine for Injection, 100mg, the generic version of Vidaza®, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc. This launch marked a significant development in the Azacitidine market, enhancing accessibility and affordability of the drug for patients suffering from myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The introduction of a cost-effective generic alternative increased market competition, driving greater adoption of Azacitidine-based therapies across healthcare providers
Frequently Asked Questions
Companies such as Novartis AG (Switzerland), Sanofi (France), Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), and Merz Pharma (Germany) are the major companies in the azacitidine market.
In September 2024, Intas Pharmaceuticals Ltd. announced the launch of Azadine-O, the first-ever oral Azacitidine therapy for Acute Myeloid Leukemia (AML) in the Indian market. In May 2022, the U.S. Food and Drug Administration (FDA) granted approval for azacitidine (Vidaza, Celgene Corp.) for use in pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
The countries covered in the azacitidine market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Austria, Poland, Norway, Ireland, Hungary, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia, Singapore, rest of Asia-Pacific, Brazil, Argentina, Chili, Colombia, Peru, Venezuela, Ecuador, Uruguay, Paraguay ,Bolivia, Trinidad And Tobago, Curaçao, rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, rest of Middle East and Africa, Guatemala, Costa Rica, Honduras, EL Salvador, Nicaragua, and rest of Central America.
